Drug Profile


Alternative Names: TG-2349

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TaiGen Biotechnology
  • Developer Dongguan HEC TaiGen Biopharmaceuticals; TaiGen Biotechnology
  • Class Antivirals; Benzofurans; Carbamates; Cyclopentanes; Cyclopropanes; Pyrimidines; Pyrroles
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 22 Nov 2017 Phase-I clinical trials in Hepatitis C (Combination therapy) in China before November 2017 (TaiGen Biotechnology pipeline, November 2017).
  • 10 Jan 2017 TaiGen Biopharmaceuticals and YiChang HEC ChangJiang Pharmaceutical form a joint venture, Dongguan HEC TaiGen Biopharmaceuticals
  • 18 Aug 2016 Investigation in Hepatitis C in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top